SCHEMBL10277330

SCHEMBL10277330

CCCNCC(COc1ccccc1/C(=C/Cc1ccccc1)OC(=O)CCC(=O)NC(C(=O)O)C(C)C)O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ PMP22 Q01453 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ABCB1 P08183 16/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ KCNH2 Q12809 2/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ SLC22A1 O15245 1/20 0.39
▸ ABCC9 O60706 1/20 0.39
▸ KCNK2 O95069 1/20 0.39
▸ ABCB11 O95342 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ ADRB1 P08588 1/20 0.39
▸ ADRB3 P13945 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11913988 0.94 MEN1 (0.39) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL1666846 0.86 ABCB1 (0.54) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL11913957 0.86 ABCB1 (0.54) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL11913991 0.82 ABCB1 (0.33) ABCB1
SCHEMBL11918305 0.78 ABCB1 (0.42) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL11913986 0.76 ABCB1 (0.42) MEN1KMT2ACYP3A4NPSR1ABCB1
SCHEMBL11913984 0.75 ABCB1 (0.61) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL1667026 0.75 ABCB1 (0.61) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL1667395 0.62 ABCB1 (0.74) MEN1KMT2APMP22CYP3A4NPSR1
SCHEMBL11918299 0.61 ABCB1 (0.77) MEN1KMT2APMP22CYP3A4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012046062-A1 USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS SHIRE, LLC (US) 2012-04-12 — — WO disclosed
Send feedback